INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. concerning allegations of securities fraud and unlawful business practices related to its drug ELEVIDYS [1][2]. Group 1: Lawsuit Details - Investors who purchased Sarepta securities during the Class Period can request to be appointed as Lead Plaintiff by August 25, 2025 [2]. - The lawsuit is based on claims that Sarepta and its officers engaged in fraudulent activities [2]. Group 2: Impact of ELEVIDYS on Stock Price - On March 18, 2025, Sarepta's stock price dropped by $27.81 (27.44%) to close at $73.54 following the announcement of a death related to ELEVIDYS treatment [3]. - Following an April 4, 2025 disclosure regarding a review of the death, the stock fell by $4.18 (7.13%) to close at $54.43 [4]. - A second fatality was reported on June 15, 2025, leading to a significant stock price decline of $15.24 (42.12%) to close at $20.94 [5]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, causing the stock to fall by $1.52 (8.01%) to close at $17.46 [6].